BIOX
Bioceres Crop Solutions Corp.
There isn't enough reported data to score BIOX yet.
BIOX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Strong | |
| Weak |
BIOX's cash flow is currently strong, but its revenue, profitability and balance sheet are under pressure.
BIOX PE Valuation
BIOX has no meaningful PE right now: it lost money over the past year.
BIOX Forward outlook
There aren't enough analyst estimates for BIOX to show an outlook.
BIOX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$3.58 | -$2.76 |
| Q1 2026 | -$3.89 | -$3.75 |
| Q4 2025 | -$3.72 | -18700% |
| Q3 2025 | -$0.83 | -4250% |
| Q2 2025 | -$0.82 | -1740% |
| Q1 2025 | -$0.14 | -450% |
| Q4 2024 | $0.02 | -94% |
| Q3 2024 | $0.02 | -91% |
BIOX lost $3.58 per share over the past year, a bigger loss than the year before.
BIOX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $57M | -23% |
| Q1 2026 | $38.2M | -37% |
| Q4 2025 | $73.8M | -31% |
| Q3 2025 | $77.6M | -17% |
| Q2 2025 | $74.4M | -40% |
| Q1 2025 | $60.6M | -28% |
| Q4 2024 | $106.7M | -24% |
| Q3 2024 | $93.3M | -20% |
BIOX's revenue has slid since its 2023 peak: $57M last quarter, down 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -18% | -8.4 points |
| Q1 2026 | -17% | -19 points |
| Q4 2025 | 10% | +2.8 points |
| Q3 2025 | 9.3% | +6.7 points |
| Q2 2025 | -9.3% | -17 points |
| Q1 2025 | 1.5% | -14 points |
| Q4 2024 | 7.4% | -4.6 points |
| Q3 2024 | 2.5% | -2 points |
BIOX's operating margin was −18% last quarter, down 8.4 points from the same quarter a year ago, near the bottom of its range since 2019.
BIOX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | $0 | -100% |
| Q4 2025 | $17.4M | +$25.4M |
| Q3 2025 | $13.7M | +253% |
| Q2 2025 | $24.6M | +16% |
| Q1 2025 | $22.1M | +$41.2M |
| Q4 2024 | -$8M | -142% |
| Q3 2024 | $3.9M | -64% |
| Q2 2024 | $21.2M | +$33.8M |
BIOX generated $56M in free cash flow over the past year, up 42% from the year before.
BIOX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +0.6% | +400K shares |
| 3 years | +0.7% | +414K shares |
| 5 years | +55% | +22.5M shares |
| Available history | +76% | +27.5M shares |
BIOX has 64M diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | $277,303 |
| Q3 2023 | $457,085 |
| Q2 2023 | $483,160 |
BIOX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 19.5x | High |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | 3.0x | Elevated |
| Q3 2024 | 2.2x | Moderate |
| Q2 2024 | 2.1x | Moderate |
| Q1 2024 | 2.6x | Moderate |
| Q4 2023 | 1.7x | Healthy |
| Q3 2023 | 2.2x | Moderate |
BIOX's net debt is about 19 years of its operating earnings (EBITDA), up from 2.1 years a year ago.
BIOX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 8.2 | Oversold |
BIOX's weekly RSI is 29 (oversold) and its Stochastic is 8 (oversold).
BIOX PE vs Basic Materials Sector
| Metric | BIOX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 19x | — |
BIOX has no meaningful PE right now: it lost money over the past year.
BIOX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.28 | 21% below |
| 20 week MA | $0.34 | 35% below |
| 50 week MA | $0.57 | 61% below |
| 100 week MA | $2.27 | 90% below |
| 200 week MA | $6.73 | 97% below |
BIOX is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
BIOX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.14 | $5.58 | +8.6% |
| 2021 | $5.58 | $14.5 | +159% |
| 2022 | $14.5 | $11.4 | -21% |
| 2023 | $11.4 | $13.7 | +20% |
| 2024 | $13.7 | $6.35 | -54% |
| 2025 | $6.35 | $1.32 | -79% |
| 2026 YTD | $1.32 | $0.22 | -83% |
BIOX's yearly returns have swung widely, from +159% in 2021 to −79% in 2025. It's down 83% so far in 2026.